Monitor the upcoming final written decision, expected within roughly 12 months. If the patent is upheld, it strengthens Spruce's exclusivity for the treatment method; if claims are cancelled, it could expose the company to competition from Neurocrine or others.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 10 $46.67entry
- T+1 · 6d ago −1.00%α −2.32% · $46.20
- T+4 · todayOpen
- T+5 · in 7h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
Executive Summary
The PTAB granted institution of post-grant review (PGR2026-00060) on Spruce Biosciences' patent covering methods for treating testicular and ovarian adrenal rest tumors. This is an interlocutory decision that opens a trial; no claims have been cancelled yet.
PTAB Trial Details
Key Facts
- PTAB instituted PGR2026-00060 on Spruce Biosciences' U.S. Patent 12,569,490
- Patent covers methods for treating testicular and ovarian adrenal rest tumors
- Petitioner is Neurocrine Biosciences, Inc.
- Decision is interlocutory, no claims have been cancelled
- Trial will proceed with a final written decision due within approximately one year
Financial Impact
Patent protects a treatment method for adrenal rest tumors; no revenue or market exposure figures stated in the decision
Risk Factors
- Institution granted means the patent faces a substantive challenge; a final decision finding claims unpatentable would remove patent protection
- No financial data in the decision to quantify revenue at risk
- Appeal to the Federal Circuit is possible after a final written decision
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 PTAB decision.
| Document | Accession Number |
|---|---|
| PTAB-TRIAL Data (Synthetic) | ptab-PGR2026-00060-ins-SPRB |
Track record
9 reports on SPRB
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 10, 20267d ago PTAB Trial Neutral 4/10 Entry $46.67 Now $42.25 −9.46% settles Nov 17
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $46.67 Now $42.25 −9.46% settles Nov 17
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Viewing Entry $46.67 Now $42.25 −9.46% settles Nov 17
- Nov 9, 20267d ago 8-K Bearish 5/10 Entry $49.34 to $42.25 Now $42.25 +14.37% ▲ +14.37% +12.68% vs SPY
- Aug 12, 202613w ago 8-K Neutral 6/10 Entry $47.07 to $52.96 Now $42.25 −10.24% ▲ +12.51% +12.96% vs SPY
- May 13, 202626w ago 8-K Mixed 5/10 Entry $57.55 to $48.25 Now $42.25 −26.59% ▼ −16.16% −15.00% vs SPY
- Apr 21, 202629w ago 424B5 Neutral 5/10 Entry $52.36 to $56.34 Now $42.25 −19.31% ▲ +7.60% +7.55% vs SPY
- Apr 20, 202630w ago 424B5 Neutral 5/10 Entry $51.69 to $54.77 Now $42.25 −18.26% ▲ +5.96% +4.87% vs SPY
- Mar 9, 202636w ago 8-K Mixed 6/10 Entry $62.11 to $60.95 Now $42.25 −31.98% ▼ −1.87% −0.51% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time PTAB Decision Intelligence
Market-moving PTAB patent decisions analyzed within minutes. Trial institutions, denials, final written decisions, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers